<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053790</url>
  </required_header>
  <id_info>
    <org_study_id>DI/18/107/03/080</org_study_id>
    <nct_id>NCT04053790</nct_id>
  </id_info>
  <brief_title>Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D)</brief_title>
  <official_title>Evaluation of the Effectiveness and Safety of Lactobacillus Fermentum and Lactobacillus Delbrueckii (Lactobacillus LB) in the Treatment of Patients With Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The combination of Lactobacillus fermentum and Lactobacillus delbrueckii
      (Lactobacillus LB) has proven to be effective and safe for treatment of acute diarrhea in
      children. Also, a clinical trial in adult patients with chronic diarrhea, showed a reduction
      in the number of daily stools. However, the evidence is not enough regarding the efficacy and
      safety of Lactobacillus LB for treatment of patients with irritable bowel syndrome with
      predominance of diarrhea (IBS-D).

      Justification for this study: Lactobacillus LB could be a promising treatment for patients
      with IBS-D; nevertheless, the scientific evidence in this context is limited and it is not
      recent. Therefore, is necessary to explore the efficacy and safety of Lactobacillus LB in
      patients with IBS-D according to Rome IV criteria.

      Hypothesis: Lactobacillus LB is useful to decrease the frequency and improve the stools
      consistency of patients diagnosed with IBS-D by Rome IV criteria.

      Primary Outcome: To compare the treatment with Lactobacillus LB at two different doses: a)
      20,000 million / day, vs. b) 10,000 million / day; and to determine if one of them is better
      than c) placebo, to decrease the frequency (weekly average of the number of stools / day) in
      patients diagnosed with IBS-D by Rome IV criteria.

      Design of the study: Clinical trial, randomized, double-blind, placebo-controlled.

      Keywords: irritable bowel syndrome with diarrhea, Lactobacillus LB, treatment, efficacy,
      safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in the number of stools per day</measure>
    <time_frame>4 weeks</time_frame>
    <description>weekly average number of evacuations / day, comparing before and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in the consistency of the stools according to Bristol scale.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bristol scale: type 1= separate hard lumps, type 2= sausage shaped but lumpy, type 3= like a sausage but with cracks on ots surface, type 4= like a sausage or sanake, smooth and soft, type 5= soft blobs with clear cut-edges, type 6= fluffy pieces with ragged edges, a mushy stool, type 7 = watery, no solid pieces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in bloating measured by a Likert scale (0-4)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Likert scale: 0=without bloating, 1=mild bloating, 2=moderate bloating, 3=severe bloating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in abdominal pain measured by a Likert scale (0-4)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Likert scale: 0=without pain, 1=mild pain, 2=moderate pain, 3=severe pain</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Irritable Bowel Syndrome With Diarrhea</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this group will receive placebo 1 tablet every 12 hours, during 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB 10000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive placebo 1 tablet containing 5,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB 20000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive placebo 1 tablet containing 10,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactobacillus LB</intervention_name>
    <description>administration of different doses of Lactobacillus LB according to the treatment groups described previously</description>
    <arm_group_label>LB 10000</arm_group_label>
    <arm_group_label>LB 20000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>a tablet of placebo every 12 hours given by mouth</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting Rome IV criteria for IBS-D, without specific medical treatment for
             the last 4 weeks prior to inclusion in this study.

        Exclusion Criteria:

          -  Presence of any chronic organic disease, consumption of any medication, patients with
             alterations in blood cell count, erythrocyte sedimentation rate, thyroid function
             tests, liver function tests, blood chemistry, anti-endomysial or anti-transglutaminase
             antibodies, positive test for presence of blood in stools, fecal calprotectin &gt;
             50mcg/g. Also, those who do not sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Mexico</name>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FATIMA HIGUERA-DE LA TIJERA, MD. MSc</last_name>
      <phone>+52(55)27892000</phone>
      <phone_ext>+7,0047</phone_ext>
      <email>fatimahiguera@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Alfredo Servín Caamaño, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Motola-Kuba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthya Díaz-Valencia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Brizuela-Alcántara, MD. MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Félix García-Gorrosquieta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Max Schmulson-Wasserman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>MARIA DE FATIMA HIGUERA DE LA TIJERA</investigator_full_name>
    <investigator_title>Head of Gastroenterology and Hepatology Department</investigator_title>
  </responsible_party>
  <keyword>irritable bowel syndrome with diarrhea</keyword>
  <keyword>Lactobacillus LB</keyword>
  <keyword>treatment</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

